SSA
CLLS

Schonfeld Strategic Advisors’s Cellectis CLLS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-14,400
Closed -$239K – 1070
2018
Q4 		$239K Buy
+14,400
New +$334K 0.01% 894

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Schonfeld Strategic Advisors's CLLS Position: Q1 2019 in Review

Schonfeld Strategic Advisors sold out of Cellectis (CLLS) in Q1 2019, closing a stake of 14,400 shares — an estimated $239K sold.

Schonfeld Strategic Advisors first reported a position in CLLS in Q4 2018 and held it in 1 quarter. The position peaked at $239K in Q4 2018. 63 funds tracked by Wall St. Rank hold CLLS as of Q1 2019.

  • Schonfeld Strategic Advisors reported no remaining Cellectis position as of Q1 2019 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 14,400 Cellectis shares in Q1 2019, an estimated $239K.
  • Schonfeld Strategic Advisors first reported a position in Cellectis in Q4 2018 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Cellectis position peaked at $239K in Q4 2018.
  • 63 funds tracked by Wall St. Rank held Cellectis as of Q1 2019.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2019, filed 15 May 2019.